Stock Market Reviews

ANRO (Alto Neuroscience, Inc.) News

Get the latest news, insights, and market updates on ANRO (Alto Neuroscience, Inc.). Explore the news page 2 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Alto shares double on plans to speed depression drug’s development
  Investors reacted positively to news that the company was using a $50 million private placement to help fund a Phase 3 study.
  Oct 20, 2025 - $ANRO
• Alto Neuroscience Receives FDA Fast Track Designation for Drug Candidate ALTO-101 for Cognitive Impairment in Schizophrenia
  Alto Neuroscience Inc. (NYSE:ANRO) is one of the best young stocks with huge upside potential. On October 3, Alto Neuroscience announced that the US FDA granted Fast Track designation to its drug candidate, ALTO-101, for the treatment of cognitive impairment associated with schizophrenia/CIAS. The designation may make ALTO-101 eligible for more frequent meetings with the FDA, […]
  Oct 17, 2025 - $ANRO
• Alto Neuroscience (ANRO): Evaluating Valuation After FDA Fast Track Milestone for Lead Schizophrenia Candidate
  Alto Neuroscience (ANRO) drew investor focus this week after announcing the FDA’s Fast Track designation for its lead candidate, ALTO-101, targeting cognitive impairment in schizophrenia. This streamlined regulatory path marks a meaningful development for the company. See our latest analysis for Alto Neuroscience. Momentum around Alto Neuroscience has accelerated dramatically after the Fast Track news, with the share price climbing more than 60% in just a few sessions before settling back to...
  Oct 6, 2025 - $ANRO
• 3 Penny Stocks With Market Caps Over $5M To Watch
  As U.S. markets continue to rise, with major indices setting fresh records despite concerns over a government shutdown, investors are exploring opportunities beyond the traditional blue-chip stocks. Penny stocks, often seen as relics of past speculative trading days, still hold potential when backed by strong financials and solid business models. These smaller or newer companies can offer unique growth prospects and hidden value for those willing to explore beyond the well-trodden paths of...
  Oct 3, 2025 - $ANRO
• Alto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with Schizophrenia
  MOUNTAIN VIEW, Calif., October 03, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia (CIAS). There are currently no approved treatments for CIAS, a core feature of schizophrenia that
  Oct 3, 2025 - $ANRO
• Alto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in Schizophrenia
  MOUNTAIN VIEW, Calif., September 09, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced positive results from an independent, prospective replication study evaluating electroencephalography (EEG) biomarkers in people with schizophrenia. The study successfully replicated previous findings, demonstrating that event-related theta-band responses, particu
  Sep 9, 2025 - $ANRO
• Undiscovered Opportunities: Penny Stocks To Watch In August 2025
  As the major U.S. stock indices continue to reach record highs, investors are increasingly looking for opportunities beyond the well-trodden paths of large-cap stocks. Penny stocks, often associated with smaller or newer companies, present a unique opportunity for growth at lower price points. Despite being a somewhat outdated term, these stocks can still offer substantial potential when backed by strong financials and solid fundamentals.
  Aug 28, 2025 - $ANRO
• Alto Neuroscience’s Depression Drug Shows Positive Biomarker Results in Phase 2 Trial
  Alto Neuroscience Inc. (NYSE:ANRO) is one of the best IPO stocks to buy according to Wall Street analysts. On June 26, Alto Neuroscience announced positive pharmacodynamic results from an exploratory Phase 2 proof-of-concept/POC trial of its drug candidate, ALTO-203. The trial enrolled 69 patients with major depressive disorder/MDD who also had elevated anhedonia, a condition […]
  Aug 20, 2025 - $ANRO
• Alto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business Highlights
  MOUNTAIN VIEW, Calif., August 13, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended June 30, 2025, and highlighted recent progress across its pipeline of clinical-stage product candidates.
  Aug 13, 2025 - $ANRO
• Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors
  MOUNTAIN VIEW, Calif., August 13, 2025--Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond Sanchez, M.D., to its Board of Directors, effective August 12, 2025. Dr. Sanchez is a highly accomplished executive with a strong background in medicine and over 20 years of strategic experience in the life sciences industries.
  Aug 13, 2025 - $ANRO